• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

代谢功能障碍相关脂肪性肝病(MASLD)中的肝祖细胞激活与小胆管反应:疾病活动度和纤维化程度的指标:一项初步研究

Hepatic progenitor cell activation and ductular reaction in metabolic dysfunction-associated steatotic liver disease (MASLD): Indicators for disease activity and the degree of fibrosis: The pilot study.

作者信息

Büyük Melek, Berker Neslihan, Bağbudar Sidar, Çavuş Bilger, Güllüoğlu Mine

机构信息

Department of Pathology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

Department of Gastroenterology and Hepatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.

出版信息

Medicine (Baltimore). 2025 Apr 11;104(15):e42108. doi: 10.1097/MD.0000000000042108.

DOI:10.1097/MD.0000000000042108
PMID:40228280
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11999437/
Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) spectrum encompasses steatosis, metabolic dysfunction-associated steatohepatitis, fibrosis, cirrhosis and metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma. We evaluated the histomorphologic findings, portal-periportal biliary epithelial cell changes, and factors that may be associated with the degree of fibrosis in liver biopsies of MASLD patients. Hematoxylin-eosin, masson-trichrome, keratin7, keratin19, CD34, and glutamine synthetase-stained biopsies of 34 patients and 10 healthy liver donors (as controls) were retrospectively analyzed. Lobular inflammation was significantly correlated to the ballooning degeneration (P = .023), portal inflammation (P = .003), ductular reaction (DR) grade (P = .027), and the degree of fibrosis (P = .003). Ballooning degeneration (P = .004), and NAS (P = .008) were significantly related to the degree of fibrosis. Portal inflammation had a significant relationship with both DR grade (P < .001) and the degree of fibrosis (P = .002). The presence of hepatic progenitor cells (HPCs) was related to NAS (P = .005) and correlated with the DR grade (P = .002) and the degree of fibrosis (P = .038). Both DR (P < .001) and biliary metaplasia (P = .024) were significantly correlated with the degree of fibrosis. In multivariate analysis, biliary metaplasia (P = .015) and DR (P = .02) were found to be independent factors related to degree of fibrosis. Our results showed that HPC and DR were closely associated with disease activity and degree of fibrosis and might be good indicators of disease progression in MASLD. As pathologists, we might integrate the degree of HPCs and the grade of DR in our pathology reports as these findings might contribute to the disease progression risk categorization of the patients.

摘要

代谢功能障碍相关脂肪性肝病(MASLD)谱系包括脂肪变性、代谢功能障碍相关脂肪性肝炎、纤维化、肝硬化以及代谢功能障碍相关脂肪性肝炎相关肝细胞癌。我们评估了MASLD患者肝活检的组织形态学表现、门周胆管上皮细胞变化以及可能与纤维化程度相关的因素。对34例患者和10例健康肝脏供体(作为对照)的苏木精-伊红、马松三色、角蛋白7、角蛋白19、CD34和谷氨酰胺合成酶染色的活检标本进行了回顾性分析。小叶炎症与气球样变性(P = 0.023)、门管区炎症(P = 0.003)、小胆管反应(DR)分级(P = 0.027)以及纤维化程度(P = 0.003)显著相关。气球样变性(P = 0.004)和NAS(P = 0.008)与纤维化程度显著相关。门管区炎症与DR分级(P < 0.001)和纤维化程度(P = 0.002)均有显著关系。肝祖细胞(HPC)的存在与NAS(P = 0.005)相关,并与DR分级(P = 0.002)和纤维化程度(P = 0.038)相关。DR(P < 0.001)和胆管化生(P = 0.024)均与纤维化程度显著相关。在多变量分析中,发现胆管化生(P = 0.015)和DR(P = 0.02)是与纤维化程度相关的独立因素。我们的结果表明,HPC和DR与疾病活动度和纤维化程度密切相关,可能是MASLD疾病进展的良好指标。作为病理学家,我们可能会在病理报告中纳入HPC的程度和DR的分级,因为这些发现可能有助于对患者的疾病进展风险进行分类。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/b9ce9b208fd0/medi-104-e42108-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/ad3ac17bf53b/medi-104-e42108-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/4ab49828d6a0/medi-104-e42108-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/8373bd49784b/medi-104-e42108-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/b9ce9b208fd0/medi-104-e42108-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/ad3ac17bf53b/medi-104-e42108-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/4ab49828d6a0/medi-104-e42108-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/8373bd49784b/medi-104-e42108-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/af44/11999437/b9ce9b208fd0/medi-104-e42108-g004.jpg

相似文献

1
Hepatic progenitor cell activation and ductular reaction in metabolic dysfunction-associated steatotic liver disease (MASLD): Indicators for disease activity and the degree of fibrosis: The pilot study.代谢功能障碍相关脂肪性肝病(MASLD)中的肝祖细胞激活与小胆管反应:疾病活动度和纤维化程度的指标:一项初步研究
Medicine (Baltimore). 2025 Apr 11;104(15):e42108. doi: 10.1097/MD.0000000000042108.
2
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.非酒精性脂肪性肝炎中的进行性纤维化:与再生改变和小胆管反应的关联。
Gastroenterology. 2007 Jul;133(1):80-90. doi: 10.1053/j.gastro.2007.05.012. Epub 2007 May 16.
3
MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls.与匹配对照相比,HIV 感染者中的 MASLD 尽管疾病活动度较低,但纤维化程度更高。
Aliment Pharmacol Ther. 2024 Nov;60(10):1351-1360. doi: 10.1111/apt.18236. Epub 2024 Sep 5.
4
Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis.纤维化与丙型肝炎中的小胆管反应相关:复制受损、祖细胞和脂肪变性的作用。
Hepatology. 2005 Apr;41(4):809-18. doi: 10.1002/hep.20650.
5
Attenuation imaging: Diagnostic differences in hepatic steatosis for chronic hepatitis B metabolic dysfunction-associated steatotic liver disease patients.衰减成像:慢性乙型肝炎代谢功能障碍相关脂肪性肝病患者肝脂肪变性的诊断差异
World J Gastroenterol. 2025 Mar 21;31(11):102795. doi: 10.3748/wjg.v31.i11.102795.
6
Hepatic angiotensin-converting enzyme 2 expression in metabolic dysfunction-associated steatotic liver disease and in patients with fatal COVID-19.代谢相关脂肪性肝病及致死性 COVID-19 患者肝组织血管紧张素转换酶 2 的表达。
World J Gastroenterol. 2024 Aug 21;30(31):3705-3716. doi: 10.3748/wjg.v30.i31.3705.
7
FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD).FIB-4 作为代谢相关脂肪性肝病(MASLD)肝纤维化前阶段的筛查和疾病监测方法。
J Diabetes Complications. 2024 Jul;38(7):108777. doi: 10.1016/j.jdiacomp.2024.108777. Epub 2024 May 21.
8
Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease.肝祖细胞激活、纤维化和肝内脂肪细胞因子在儿童非酒精性脂肪性肝病中的产生。
Hepatology. 2012 Dec;56(6):2142-53. doi: 10.1002/hep.25742.
9
Serum lipidomic signatures in patients with varying histological severity of metabolic-dysfunction associated steatotic liver disease.代谢功能障碍相关脂肪性肝病不同组织学严重程度患者的血清脂质组学特征
Metabolism. 2025 Jan;162:156063. doi: 10.1016/j.metabol.2024.156063. Epub 2024 Nov 8.
10
Disease Progression for Histologic Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Real-World: A Nationwide US Study.现实世界中代谢功能障碍相关脂肪性肝病组织学诊断的疾病进展:一项美国全国性研究
Dig Dis. 2025;43(1):36-45. doi: 10.1159/000541945. Epub 2024 Oct 14.

本文引用的文献

1
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.EASL-EASD-EASO 临床实践指南:代谢功能障碍相关脂肪性肝病(MASLD)的管理。执行摘要。
Diabetologia. 2024 Nov;67(11):2375-2392. doi: 10.1007/s00125-024-06196-3.
2
Ductular reaction in non-alcoholic fatty liver disease: When Macbeth is perverted.非酒精性脂肪性肝病中的小胆管反应:当麦克白被扭曲时。
World J Hepatol. 2023 Jun 27;15(6):725-740. doi: 10.4254/wjh.v15.i6.725.
3
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
多学会专家共识:新的非酒精性脂肪性肝病命名。
Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24.
4
Global epidemiology of cirrhosis - aetiology, trends and predictions.全球肝硬化的流行病学:病因、趋势和预测。
Nat Rev Gastroenterol Hepatol. 2023 Jun;20(6):388-398. doi: 10.1038/s41575-023-00759-2. Epub 2023 Mar 28.
5
Non-alcoholic fatty liver disease.非酒精性脂肪性肝病。
Lancet. 2021 Jun 5;397(10290):2212-2224. doi: 10.1016/S0140-6736(20)32511-3. Epub 2021 Apr 21.
6
Ductular Reaction in Liver Diseases: Pathological Mechanisms and Translational Significances.肝脏疾病中的胆小管反应:病理机制与转化意义。
Hepatology. 2019 Jan;69(1):420-430. doi: 10.1002/hep.30150. Epub 2018 Dec 27.
7
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.非酒精性脂肪性肝病和非酒精性脂肪性肝炎的全球负担:趋势、预测、危险因素和预防。
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20.
8
Non-alcoholic fatty liver disease.非酒精性脂肪性肝病
BMC Med. 2017 Feb 28;15(1):45. doi: 10.1186/s12916-017-0806-8.
9
Pathology of non-alcoholic fatty liver disease.非酒精性脂肪性肝病的病理学。
Liver Int. 2017 Jan;37 Suppl 1:85-89. doi: 10.1111/liv.13301.
10
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.欧洲肝脏研究学会-欧洲糖尿病研究学会-欧洲肥胖症研究学会非酒精性脂肪性肝病管理临床实践指南
J Hepatol. 2016 Jun;64(6):1388-402. doi: 10.1016/j.jhep.2015.11.004. Epub 2016 Apr 7.